Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Abstract Background In 2023, there were 39.9 million people living with HIV (PLWH) worldwide and 630 000 deaths related to HIV. New strategies are needed, long-acting antiretrovirals (LAAs) now widely considered have great potential help end the epidemic. This systematic review meta-analysis compare safety efficacy of LAA versus standard oral treatment (SOT) for Methods PubMed Embase databases, supplemented by ClinicalTrials.gov grey literature, searched. Randomized controlled trials (RCTs) reporting and/or SOT PLWH until June 2024 included. Efficacy (HIV RNA < 50 copies/mL) ≥ copies/mL, adverse events (AEs), discontinuation, CD4 count, metabolic parameters drug resistance assessed. Prespecified subgroup analyses conducted. The risk bias was assessed Cochrane RoB 2.0. Certainty evidence using GRADE. Results Six RCTs eligible inclusion, involving 2829 participants. non-inferior in suppressing copies/mL [Risk Difference (RD), −0.00; 95% CI, −0.03–0.02; P = 0.83; I2 51%; high quality (QoE)]. associated higher (percentage pooled estimate, 57%; 33%–78% 9%; 2%–30%; moderate QoE) grade 1–4 AEs than Ratio (RR), 1.22; 1.12–1.33; 0.001; 62%; QoE]. Conclusions has compared SOT. However, participants receiving at a developing resistance, cross-resistance AEs.

Language: Английский

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

AIDS Research and Therapy, Journal Year: 2025, Volume and Issue: 22(1)

Published: March 15, 2025

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to disoproxil fumarate (TDF). We retrospectively evaluated changes and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year treatment with TAF versus TDF (3.5 kg − 1 kg, P-value < 0.001). However, weight-gain attenuated longer follow-up, no dysregulation noted treatment. Attribution risk remains questionable.

Language: Английский

Effect of Two Forms of Tenofovir on Duodenal Enterocytes – a Hypothesis for Different Effect of TDF and TAF on Body Weight and Plasma Lipids

Clinical Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: July 19, 2024

Tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF) leads lower body weight and plasma lipids by an unknown mechanism. We hypothesize that TDF, when absorbed, may damage enterocytes of the proximal duodenum, leading reduced absorption nutrients.

Language: Английский